Thus, our data provide the novel in vivo evidence for the critical role of Notch inhibition in prevention of AAA in ApoE−/− mice after Ang II infusion, and suggest that γ-secretase DBZ might be a new therapeutic drug for the treatment and prevention of AAAs. This evidence concerns the gene APOE and triple-A syndrome.